Eupraxia Pharmaceuticals (EPRX) Q3 2025 earnings summary

Executive summary

• Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI in the RESOLVE trial, with two-thirds of Cohort 5 patients in clinical remission at one year.

• Enrollment continues in the Phase 2b portion of the RESOLVE trial, with topline data expected by Q3 2026.

• Completed a $80.5 million public offering, strengthening resources for pipeline advancement.

Financial highlights

• Net loss of $6.4 million for Q3 2025, compared to $6.0 million for Q3 2024, primarily due to increased R&D and G&A costs.

• Cash balance of $89.0 million as of September 30, 2025, up from $33.1 million at year-end 2024.

• $80.5 million raised through a public offering of 14,636,363 shares at $5.50 per share.

Outlook and guidance

• Cash runway expected to fund operations and pipeline development into the first half of 2028.

• Topline data from the Phase 2b RESOLVE trial anticipated by Q3 2026.

• Proceeds from the offering will support clinical development of EP-104GI and broader pipeline advancement.